PLK1 and melanoma: Since AURK A/B and PLK1 are overexpressed in many cancer types, including melanoma, and considering that these serine/threonine mitotic kinases are currently regarded as attractive anticancer targets [51,53,54], 3a represents a promising pre-clinical drug prototype.